Straathof C S, van den Bent M J, Loos W J, Vecht C J, Schellens J H
Department of Neuro-oncology, Dr. Daniel den Hoed Cancer Center and University Hospital Rotterdam, The Netherlands.
J Neurooncol. 1999 Apr;42(2):117-22. doi: 10.1023/a:1006166716683.
The accumulation of the topoisomerase I inhibitor topotecan in brain tumor as well as in brain around tumor (BAT) and normal brain following an intravenous bolus of topotecan of 0.5 mg/kg was investigated in rats bearing a 9L glioma. Also the influence of dexamethasone (Dex) on the uptake of topotecan was examined. Tumor, BAT and brain tissue as well as whole blood were collected at 1 h after an i.v. bolus of topotecan. Concentrations of total topotecan in tumor, BAT and brain were quantified with high-performance liquid chromatography (HPLC) and compared with concentrations in plasma of total topotecan. In brain tumor tissue the mean total topotecan concentration was 96 +/- 33 ng/g which was 20-fold higher than the accumulation of topotecan in normal brain tissue. In BAT intermediate concentrations of 13 +/- 4.9 ng/g were reached. Mean total topotecan concentration in plasma was 100 +/- 25 ng/ml. We did not find an influence of Dex on the uptake of topotecan in either tissue. We conclude that high tissue concentrations of topotecan can be reached in experimental brain tumors in rats. This observation may be useful in the design of clinical studies with topotecan.
在携带9L胶质瘤的大鼠中,研究了静脉推注0.5mg/kg拓扑替康后,拓扑异构酶I抑制剂拓扑替康在脑肿瘤、肿瘤周围脑组织(BAT)以及正常脑组织中的蓄积情况。同时,还检测了地塞米松(Dex)对拓扑替康摄取的影响。在静脉推注拓扑替康1小时后,收集肿瘤、BAT、脑组织以及全血。用高效液相色谱法(HPLC)对肿瘤、BAT和脑组织中总拓扑替康的浓度进行定量,并与血浆中总拓扑替康的浓度进行比较。在脑肿瘤组织中,总拓扑替康的平均浓度为96±33ng/g,比拓扑替康在正常脑组织中的蓄积量高20倍。在BAT中,达到了13±4.9ng/g的中间浓度。血浆中总拓扑替康的平均浓度为100±25ng/ml。我们没有发现Dex对任何一种组织中拓扑替康的摄取有影响。我们得出结论,在大鼠实验性脑肿瘤中可以达到高组织浓度的拓扑替康。这一观察结果可能对拓扑替康临床研究的设计有用。